Table 2 Patient pre-therapy characteristics and treatment details
Patient 1 | Patient 2 | Patient 3 | |
|---|---|---|---|
Age | 64 | 60 | 61 |
BMI | 26.5 | 25.4 | 23.9 |
Prostate volume (ml) | 45.6 | 51 | 21 |
Gleason score | 3 + 3 | 3 + 3 | 3 + 3 |
Clinical stage | T1c | T1c | T1c |
Pre-therapy PSA (ng/ml) | 1.96 | 4.13 | 2.14 |
Previous therapy | None | None | Leuprolide 3-month duration (stopped 6 months prior to protocol entry) |
Pre-therapy multiparametric MRI and CT | No visible lesion | No visible lesion | No visible lesion |
Sectors positive on biopsy pre-therapy (% and length of core) | Right posterior lateral base (2 %, 0.2 mm) Left lateral base (5 %, 0.5 mm) | Left anterior lateral apex (1 %, 0.2 mm) Left anterior medial apex (1 %, 0.5 mm) Left posterior lateral apex (10 %, 5 mm) | Left anterior medial apex (10 %, 2 mm) Left posterior lateral apex (5 %, 1 mm) Left posterior medial apex (20 %, 2.5 mm) Left posterior medial base (10 %, 2 mm) |
Number of treatment (macro) sonications | 11 | 6 | 12 |
Total sonication time | 3 h 55 min | 1 h 3 min | 1 h 46 min |
Total time in scanner | 6 h 18 min | 3 h 34 min | 3 h 40 min |
Pain score postoperatively | 0–1 | 0–1 | 0–1 |